RATIONALE: Although selective serotonin reuptake inhibitors (SSRIs) produce clinical therapeutic effects on depression and anxiety through augmentation of serotonergic neurotransmission, there is little known about the potential contributions of the 5-HT(6) receptor in the treatment of mood disorders. OBJECTIVES: The aim of this study was to test the potential antidepressant-like and anxiolytic-like effects of the 5-HT(6) receptor agonists WAY-208466 and WAY-181187 using established behavioral tests in rats. METHODS: In order to determine if the 5-HT(6) receptor agonists possess antidepressant-like activity, rats were treated with WAY-208466 or WAY-181187 and tested in the modified rat forced swim test (FST). Also, the potential anxiolytic-like effects of WAY-208466 and WAY-181187 were measured using the defensive burying (DB) test and novelty-induced hypophagia (NIH) test. RESULTS: WAY-208466 and WAY-181187 produced both antidepressant-like and anxiolytic-like effects. Both compounds decreased immobility and increased swimming behavior in the FST. The effects of the 5-HT(6) receptor agonists were similar to those seen after treatment with the SSRI fluoxetine. Both 5-HT(6) receptor agonists also decreased burying duration in the DB test, indicative of anxiolytic activity in the test. The anxiolytic effects of WAY-208466 were reproduced in the NIH test. Assessment of the anxiolytic effects of WAY-181187 in the NIH was confounded by alterations in home cage feeding behavior. CONCLUSIONS: These findings suggest that 5-HT(6) receptor agonists may represent a new class of potential antidepressant and anxiolytic compounds and could possess a number of advantages over currently available treatments, including rapid onset of anxiolytic efficacy.
RATIONALE: Although selective serotonin reuptake inhibitors (SSRIs) produce clinical therapeutic effects on depression and anxiety through augmentation of serotonergic neurotransmission, there is little known about the potential contributions of the 5-HT(6) receptor in the treatment of mood disorders. OBJECTIVES: The aim of this study was to test the potential antidepressant-like and anxiolytic-like effects of the 5-HT(6) receptor agonists WAY-208466 and WAY-181187 using established behavioral tests in rats. METHODS: In order to determine if the 5-HT(6) receptor agonists possess antidepressant-like activity, rats were treated with WAY-208466 or WAY-181187 and tested in the modified rat forced swim test (FST). Also, the potential anxiolytic-like effects of WAY-208466 and WAY-181187 were measured using the defensive burying (DB) test and novelty-induced hypophagia (NIH) test. RESULTS:WAY-208466 and WAY-181187 produced both antidepressant-like and anxiolytic-like effects. Both compounds decreased immobility and increased swimming behavior in the FST. The effects of the 5-HT(6) receptor agonists were similar to those seen after treatment with the SSRI fluoxetine. Both 5-HT(6) receptor agonists also decreased burying duration in the DB test, indicative of anxiolytic activity in the test. The anxiolytic effects of WAY-208466 were reproduced in the NIH test. Assessment of the anxiolytic effects of WAY-181187 in the NIH was confounded by alterations in home cage feeding behavior. CONCLUSIONS: These findings suggest that 5-HT(6) receptor agonists may represent a new class of potential antidepressant and anxiolytic compounds and could possess a number of advantages over currently available treatments, including rapid onset of anxiolytic efficacy.
Authors: Katherine E Burnham; Mark G Baxter; John R Bainton; Eric Southam; Lee A Dawson; David M Bannerman; Trevor Sharp Journal: Psychopharmacology (Berl) Date: 2009-11-10 Impact factor: 4.530
Authors: Jennifer C Roberts; Charlie Reavill; Simon Z East; Paul J Harrison; Sara Patel; Carol Routledge; Ronald A Leslie Journal: Brain Res Date: 2002-04-26 Impact factor: 3.252
Authors: Atom J Lesiak; Matthew Brodsky; Nathalie Cohenca; Alexandra G Croicu; John F Neumaier Journal: Mol Pharmacol Date: 2018-04-20 Impact factor: 4.436
Authors: Samantha L White; Fair M Vassoler; Heath D Schmidt; R Christopher Pierce; Mathieu E Wimmer Journal: Addict Biol Date: 2015-04-29 Impact factor: 4.280
Authors: Monika Marcinkowska; Adam Bucki; Joanna Sniecikowska; Agnieszka Zagórska; Nikola Fajkis-Zajączkowska; Agata Siwek; Monika Gluch-Lutwin; Paweł Żmudzki; Magdalena Jastrzebska-Wiesek; Anna Partyka; Anna Wesołowska; Michał Abram; Katarzyna Przejczowska-Pomierny; Agnieszka Cios; Elżbieta Wyska; Kamil Mika; Magdalena Kotańska; Paweł Mierzejewski; Marcin Kolaczkowski Journal: J Med Chem Date: 2021-08-26 Impact factor: 7.446